PRRT2 and neoplasm: In-depth analyses of the impact of key PKC mutations, the failures and promises of clinical trials conducted over the years and of the key immunological pathways involving distinctive isoforms in the tumor microenvironment, are critical to improve the drug targeting of PKC.